Aucta is a company creating better products from proven molecules.

Aucta Pharmaceuticals’ core strategy focuses on developing Improved New Drugs through the FDA 505(b)(2) regulatory pathway, leveraging proven molecules to create clinically differentiated therapies with lower development risk and shorter timelines. The company focuses on Central Nervous System (CNS) disorders, metabolic diseases, and orphan indications, areas characterized by high unmet clinical needs. Its business model combines two synergistic pillars — an innovation-driven 505(b)(2) pipeline and a high-barrier branded generics platform — balancing sustainable cash flow with long-term value creation. Through a dual-hub structure in the U.S. and China, We are a pioneer and leading developer of innovative drug delivery solution of differentiated treatments to improve the existing standard of care. The company’s goal is to build a fully integrated pharmaceutical ecosystem spanning R&D, manufacturing, and commercialization, supported by strong IP protection, proprietary technologies, and operational excellence.